RU2666144C2 - Кристаллические формы { [1-циано-5-(4-хлорофенокси)-4-гидроксиизохинолин-3-карбонил]-амино} -уксусной кислоты - Google Patents

Кристаллические формы { [1-циано-5-(4-хлорофенокси)-4-гидроксиизохинолин-3-карбонил]-амино} -уксусной кислоты Download PDF

Info

Publication number
RU2666144C2
RU2666144C2 RU2015134420A RU2015134420A RU2666144C2 RU 2666144 C2 RU2666144 C2 RU 2666144C2 RU 2015134420 A RU2015134420 A RU 2015134420A RU 2015134420 A RU2015134420 A RU 2015134420A RU 2666144 C2 RU2666144 C2 RU 2666144C2
Authority
RU
Russia
Prior art keywords
compound
diffraction pattern
chlorophenoxy
cyano
acetic acid
Prior art date
Application number
RU2015134420A
Other languages
English (en)
Russian (ru)
Other versions
RU2015134420A (ru
Inventor
Клаудия ВИТШИ
Майкл Д. Томпсон
Юн Мин ПАРК
Майкл П. АРЕНД
Original Assignee
Фиброген, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50073508&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2666144(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Фиброген, Инк. filed Critical Фиброген, Инк.
Publication of RU2015134420A publication Critical patent/RU2015134420A/ru
Application granted granted Critical
Publication of RU2666144C2 publication Critical patent/RU2666144C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
RU2015134420A 2013-01-24 2014-01-23 Кристаллические формы { [1-циано-5-(4-хлорофенокси)-4-гидроксиизохинолин-3-карбонил]-амино} -уксусной кислоты RU2666144C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361756361P 2013-01-24 2013-01-24
US61/756,361 2013-01-24
PCT/US2014/012780 WO2014116849A1 (en) 2013-01-24 2014-01-23 Crystalline forms of {[1-cyano-5-(4-chlorophenoxy)-4-hydroxy-isoquinoline-3-carbonyl]-amino}-acetic acid

Publications (2)

Publication Number Publication Date
RU2015134420A RU2015134420A (ru) 2017-03-03
RU2666144C2 true RU2666144C2 (ru) 2018-09-06

Family

ID=50073508

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2015134420A RU2666144C2 (ru) 2013-01-24 2014-01-23 Кристаллические формы { [1-циано-5-(4-хлорофенокси)-4-гидроксиизохинолин-3-карбонил]-амино} -уксусной кислоты

Country Status (15)

Country Link
US (1) US9643928B2 (enExample)
EP (1) EP2951159B1 (enExample)
JP (1) JP6437456B2 (enExample)
KR (1) KR102233081B1 (enExample)
CN (1) CN105452227B (enExample)
AU (1) AU2014209319B2 (enExample)
CA (1) CA2899024C (enExample)
DK (1) DK2951159T3 (enExample)
ES (1) ES2694297T3 (enExample)
IL (1) IL240066B (enExample)
MX (1) MX360048B (enExample)
RU (1) RU2666144C2 (enExample)
SG (2) SG10202009266PA (enExample)
TW (1) TWI685487B (enExample)
WO (1) WO2014116849A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103145616B (zh) 2003-06-06 2015-09-30 菲布罗根有限公司 含氮杂芳基化合物及其在增加内源性促红细胞生成素中的用途
WO2010056767A1 (en) 2008-11-14 2010-05-20 Fibrogen, Inc. Thiochromene derivatives as hip hydroxylase inhibitors
EP3470397B1 (en) 2012-07-16 2021-12-29 Fibrogen, Inc. Crystalline forms of a prolyl hydroxylase inhibitor
US8883823B2 (en) 2012-07-16 2014-11-11 Fibrogen, Inc. Crystalline forms of a prolyl hydroxylase inhibitor
SG11201500234YA (en) 2012-07-16 2015-02-27 Fibrogen Inc Process for making isoquinoline compounds
SG10202009266PA (en) 2013-01-24 2020-10-29 Fibrogen Inc Crystalline forms of {[1-cyano-5-(4-chlorophenoxy)-4-hydroxy-isoquinoline-3-carbonyl]-amino}-acetic acid
IL296484B2 (en) 2013-06-06 2025-03-01 Fibrogen Inc Pharmaceutical formulations of HIF hydroxylase inhibitor
CA2959688C (en) 2014-09-02 2024-02-27 Sunshine Lake Pharma Co., Ltd. Quinolone compounds and their use to treat diseases related to hypoxia inducible factor and/or erythropoietin
EP4121009A4 (en) * 2020-03-17 2024-04-17 Zydus Lifesciences Limited Formulation comprising hif prolyl hydroxylase inhibitors
WO2021216530A1 (en) 2020-04-20 2021-10-28 Akebia Therapeutics, Inc. Treatment of viral infections, of organ injury, and of related conditions using a hif prolyl hydroxylase inhibitor or a hif-alpha stabilizer

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009075826A1 (en) * 2007-12-07 2009-06-18 Fibrogen, Inc. Methods for increasing white blood cells
RU2379291C2 (ru) * 2003-06-06 2010-01-20 Фиброген, Инк. Азотсодержащие гетероарильные соединения и их применение при повышении эндогенного эритропоэтина
US7928120B2 (en) * 2006-01-27 2011-04-19 Fibrogen, Inc. Cyanoisoquinoline compounds and methods of use thereof

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4036964A (en) 1973-10-11 1977-07-19 Beecham Group Limited Isocarbostyril-3-carboxylic acid derivatives for the prophylaxis of asthma, hayfever and rhinitis
US3989704A (en) 1973-10-30 1976-11-02 Sandoz, Inc. 3-Substituted-4-aryl isoquinolines
DE2818423A1 (de) 1978-04-27 1979-11-08 Hoechst Ag Neue isochinolinderivate und verfahren zu ihrer herstellung
DE3233424A1 (de) 1982-09-09 1984-03-15 Hoechst Ag, 6230 Frankfurt Isochinolinderivate, verfahren zu ihrer herstellung, pharmazeutische praeparate auf basis dieser verbindungen und ihre verwendung
US4559403A (en) 1983-05-19 1985-12-17 Hoffmann-La Roche Inc. Substituted isoquinolines
US4584379A (en) 1985-01-22 1986-04-22 Merrell Dow Pharmaceuticals Inc. Isoquinoline thromboxane synthetase inhibitors
US4822800A (en) 1986-06-09 1989-04-18 Ortho Pharmaceutical Corporation Isoquinolinol compounds having cardiotonic and phosphodiesterase fraction III inhibiting properties and/or renal vasodilating properties
US4966906A (en) 1987-11-27 1990-10-30 Hoechst-Roussel Pharmaceuticals Inc. 1-aryl-3-isoquinolinecarboxamides
US4952588A (en) 1987-11-27 1990-08-28 Hoechst-Roussel Pharmaceuticals Inc. 1-aryl-3-quinoline-and 1-aryl-3-isoquinoline-carboxamides
EP0532466A3 (en) 1991-09-12 1993-06-16 Ciba-Geigy Ag Derivatives of 5-amino-4-hydroxy-hexanoic acid and their therapeutical use
EP0626178A1 (de) 1993-05-17 1994-11-30 Ciba-Geigy Ag Verwendung von Hemmstoffen von HIV-Aspartatproteasen zur Bekämpfung von Tumorerkrankungen
ATE149485T1 (de) 1993-11-02 1997-03-15 Hoechst Ag Substituierte heterocyclische carbonsäureamidester, ihre herstellung und ihre verwendung als arzneimittel
EP0650961B1 (de) 1993-11-02 1997-03-05 Hoechst Aktiengesellschaft Substituierte heterocyclische Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
CA2138929A1 (en) 1993-12-30 1995-07-01 Klaus Weidmann Substituted heterocyclic carboxamides, their preparation and their use as pharmaceuticals
US5563143A (en) 1994-09-21 1996-10-08 Pfizer Inc. Catechol diether compounds as inhibitors of TNF release
AU4515696A (en) 1994-12-12 1996-07-03 Merck & Co., Inc. Substituted 2-aminopyridines as inhibitors of nitric oxide synthase
IL135495A (en) 1995-09-28 2002-12-01 Hoechst Ag Intermediate compounds for the preparation of quinoline-converted amines - 2 - carboxylic acid
PT944619E (pt) 1996-11-27 2007-01-31 Bristol Myers Squibb Pharma Co Novos antagonistas dos receptores da integrina
GB9707830D0 (en) 1997-04-18 1997-06-04 Smithkline Beecham Plc Novel compounds
WO1998050346A2 (en) 1997-04-18 1998-11-12 Smithkline Beecham Plc Acetamide and urea derivatives, process for their preparation and their use in the treatment of cns disorders
DE19746287A1 (de) 1997-10-20 1999-04-22 Hoechst Marion Roussel De Gmbh Substituierte Isochinolin-2-Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
FR2779963A1 (fr) 1998-06-22 1999-12-24 Centre Nat Rech Scient Utilisation d'un compose possedant une affinite pour le recepteur mitochondrial des benzodiazepines en therapie du cancer
IT1302677B1 (it) 1998-10-15 2000-09-29 Zambon Spa Derivati benzazinici inibitori della fosfodiesterasi 4
WO2000064877A1 (en) 1999-04-26 2000-11-02 Neurogen Corporation 2-aminoquinolinecarboxamides: neurokinin receptor ligands
IT1320162B1 (it) 2000-02-09 2003-11-18 Rotta Research Lab Derivati della tirosina ad attivita' anti leucotrienica, procedimentoper la loro preparazione e loro uso farmaceutico.
US7622503B2 (en) 2000-08-24 2009-11-24 University Of Tennessee Research Foundation Selective androgen receptor modulators and methods of use thereof
FI20002044A0 (fi) 2000-09-15 2000-09-15 Orion Yhtymae Oyj Comt-entsyymiä estäviä naftaleenijohdannaisia
DE10110750A1 (de) 2001-03-07 2002-09-12 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
JP4590157B2 (ja) 2001-03-21 2010-12-01 アイシス イノヴェイション リミテッド アッセイ、方法および手段
US6716866B2 (en) 2001-06-13 2004-04-06 Genesoft Pharmaceuticals, Inc. Aryl-benzimidazole compounds having antiinfective activity
CA2450625A1 (en) 2001-06-13 2002-12-19 Genesoft Pharmaceuticals, Inc. Isoquinoline compounds having antiinfective activity
CA2448737C (en) 2001-07-20 2010-06-01 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
EP2335700A1 (en) 2001-07-25 2011-06-22 Boehringer Ingelheim (Canada) Ltd. Hepatitis C virus polymerase inhibitors with a heterobicylic structure
US7294457B2 (en) 2001-08-07 2007-11-13 Boehringer Ingelheim (Canada) Ltd. Direct binding assay for identifying inhibitors of HCV polymerase
US6762318B2 (en) 2001-12-03 2004-07-13 Novo Nordisk A/S Glucagon antagonists
HU229475B1 (en) 2001-12-06 2014-01-28 Fibrogen Methods of increasing endogenous erythropoietin (epo)
GB0206711D0 (en) 2002-03-21 2002-05-01 Isis Innovation HIF Inhibitor
US8124582B2 (en) 2002-12-06 2012-02-28 Fibrogen, Inc. Treatment of diabetes
US7618940B2 (en) 2002-12-06 2009-11-17 Fibrogen, Inc. Fat regulation
WO2005007192A2 (en) 2003-06-06 2005-01-27 Fibrogen, Inc. Cytoprotection through the use of hif hydroxylase inhibitors
CN103145616B (zh) 2003-06-06 2015-09-30 菲布罗根有限公司 含氮杂芳基化合物及其在增加内源性促红细胞生成素中的用途
US8614204B2 (en) 2003-06-06 2013-12-24 Fibrogen, Inc. Enhanced erythropoiesis and iron metabolism
EP1646611A1 (en) 2003-07-15 2006-04-19 Merck & Co., Inc. Hydroxypyridine cgrp receptor antagonists
US7544699B2 (en) 2003-08-08 2009-06-09 Transtech Pharma, Inc. Aryl and heteroaryl compounds, compositions, and methods of use
US7208601B2 (en) 2003-08-08 2007-04-24 Mjalli Adnan M M Aryl and heteroaryl compounds, compositions, and methods of use
WO2006020133A2 (en) 2004-07-15 2006-02-23 Powerprecise Solutions, Inc. One time operating state detecting method and apparatus
EP1676834A1 (en) 2004-12-30 2006-07-05 Sanofi-Aventis Deutschland GmbH Fused bicyclic carboxamide derivates for use as CXCR2 inhibitors in the treatment of inflammation
US8703795B2 (en) 2005-03-02 2014-04-22 Fibrogen, Inc. Thienopyridine compounds, and methods of use thereof
CN101849943A (zh) 2005-06-06 2010-10-06 菲布罗根公司 使用HIFα稳定剂的改进的贫血治疗
AU2006259352A1 (en) 2005-06-15 2006-12-28 Fibrogen, Inc. Use of HIF 1alfa modulators for treatment of cancer
US20070259960A1 (en) 2006-02-16 2007-11-08 Fibrogen, Inc. Compounds and methods for treatment of stroke
AU2007234408B2 (en) 2006-04-04 2011-05-19 Fibrogen, Inc. Pyrrolo- and thiazolo-pyridine compounds as HIF modulators
US20070293575A1 (en) 2006-06-15 2007-12-20 Fibrogen, Inc. Compounds and methods for treatment of cancer-related anemia
US7713986B2 (en) 2006-06-15 2010-05-11 Fibrogen, Inc. Compounds and methods for treatment of chemotherapy-induced anemia
SG10202009266PA (en) 2013-01-24 2020-10-29 Fibrogen Inc Crystalline forms of {[1-cyano-5-(4-chlorophenoxy)-4-hydroxy-isoquinoline-3-carbonyl]-amino}-acetic acid

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2379291C2 (ru) * 2003-06-06 2010-01-20 Фиброген, Инк. Азотсодержащие гетероарильные соединения и их применение при повышении эндогенного эритропоэтина
US7928120B2 (en) * 2006-01-27 2011-04-19 Fibrogen, Inc. Cyanoisoquinoline compounds and methods of use thereof
WO2009075826A1 (en) * 2007-12-07 2009-06-18 Fibrogen, Inc. Methods for increasing white blood cells

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Caira M.R. и др.: "Crystalline polymorthism of organic compounds" TOPICS IN CURRENT CHEMISTRY, 198, 1998, стр.163-208, стр.165-166. *

Also Published As

Publication number Publication date
KR20150129679A (ko) 2015-11-20
TWI685487B (zh) 2020-02-21
CA2899024A1 (en) 2014-07-31
WO2014116849A1 (en) 2014-07-31
JP2016505071A (ja) 2016-02-18
EP2951159A1 (en) 2015-12-09
SG11201505748UA (en) 2015-08-28
KR102233081B1 (ko) 2021-03-29
DK2951159T3 (en) 2018-11-19
HK1217331A1 (en) 2017-01-06
ES2694297T3 (es) 2018-12-19
MX360048B (es) 2018-10-19
CA2899024C (en) 2022-01-04
CN105452227A (zh) 2016-03-30
US20160002170A1 (en) 2016-01-07
AU2014209319B2 (en) 2018-04-19
US9643928B2 (en) 2017-05-09
MX2015009617A (es) 2016-04-20
SG10202009266PA (en) 2020-10-29
JP6437456B2 (ja) 2018-12-12
TW201444800A (zh) 2014-12-01
EP2951159B1 (en) 2018-08-22
AU2014209319A1 (en) 2015-08-27
IL240066A0 (en) 2015-09-24
IL240066B (en) 2019-08-29
RU2015134420A (ru) 2017-03-03
CN105452227B (zh) 2018-05-29

Similar Documents

Publication Publication Date Title
EP2951159B1 (en) Crystalline forms of {[1-cyano-5-(4-chlorophenoxy)-4-hydroxy-isoquinoline-3-carbonyl]-amino}-acetic acid
AU2013290438C1 (en) Crystalline forms of the prolyl hydroxylase inhibitor [(4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid
US9918977B2 (en) Crystalline forms of a prolyl hydroxylase inhibitor
HK1217331B (en) Crystalline forms of {[1-cyano-5-(4-chlorophenoxy)-4-hydroxy-isoquinoline-3-carbonyl]-amino}-acetic acid
HK40077210A (en) Crystalline forms of a prolyl hydroxylase inhibitor
HK40006583B (en) Crystalline forms of a prolyl hydroxylase inhibitor
HK1241365B (en) Crystalline forms of a prolyl hydroxylase inhibitor